Figure 1

<p><b>A & B</b>: Rare or no (arrows) H/RS cells stained with CD20 in refractory cHL (<b>A</b>) compared to the overexpression of CD20 on H/RS cells in a responder cHL (arrows) (<b>B</b>) (original magnification ×400). <b>C & D</b>: Numerous H/RS cells stained with bcl2 in a refractory cHL (arrows)(<b>C</b>) comparing to rare cells in a responder case (arrow)(<b>D</b>) (original magnification ×400). <b>E & F</b>: TiA1 expressed on numerous small lymphocytes in a refractory cHL (arrows) (<b>E</b>) and less frequent cells stained with this antibody in a responder cHL (arrows) (<b>F</b>) (original magnification ×400). <b>G & H</b>: c-kit stained frequent mast cells in a refractory cHL (arrows) (<b>G</b>) compared to rare mast cells expressing c-kit in a responder cHL (arrows) (<b>H</b>) (original magnification ×400).</p

Flowchart.

<p>Peg-interferon-alpha (Peg-IFN), B-cell non-Hodgkin lymphoma (B-NHL) First generation of protease inhibitors (PI1s), Direct-acting antiviral drugs (DAAs).</p

Safety in the cohort treated by Peg-IFN-based therapy.

<p>Safety in the cohort treated by Peg-IFN-based therapy.</p

Overall survival of the patients with B-NHL and controls.

<p>Overall survival of the patients with B-NHL and controls.</p

Characteristics of patients & IHC markers (univariate analysis).

<p><b>Legends</b>: pts = patients sbtype = subtype L = lymphocytes MC = mast cells nber = number IHC:immunohistochemical CV: continuous variable HRS: Hodgkin and Reed Sternberg cells.</p

Predictive factors associated with sustained virologic response in the cohort treated by Peg-IFN-based therapy.

<p>Predictive factors associated with sustained virologic response in the cohort treated by Peg-IFN-based therapy.</p

Sustained virologic response of the patients from the cohort treated by Peg-IFN-based therapy, * p< 0.02.

<p>First generation of protease inhibitors (PI1s). A: global sustained virologic response. B: sustained virologic response according to HCV genotype.</p

Haematological response of the patients from the B-NHL group treated by Peg-IFN-based therapy with or without sustained virologic response, * p = 0.02.

<p>Haematological response of the patients from the B-NHL group treated by Peg-IFN-based therapy with or without sustained virologic response, * p = 0.02.</p

Characteristics and follow-up of the patients with HCV infection and B-NHL treated by direct-acting antiviral drugs (DAAs).

<p>Marginal zone lymphomas (MZLs); Diffuse large B-cell lymphomas (DLBCLs).</p

Characteristics of the patients treated by Peg-IFN-based therapy.

<p>Characteristics of the patients treated by Peg-IFN-based therapy.</p